Sanofi hits bullseye in phase III trial of treatment for RSV

Sanofi has completed a major phase III study of a drug for respiratory disease RSV in infants, and now, the company aims for official approval for the treatment.

Photo: STR/AFP / AFP

Sanofi plans to start applying for approvals for the drug candidate nirsevimab over the course of 2022.

This is because the drug has reached its primary endpoints in a phase III study as a treatment for respiratory infections in infants with respiratory syncytial virus (RSV). The drug showed significant reductions in the number of infections in the lower respiratory tract which required hospitalization.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs